David Vicente
0000-0001-9945-7008
Publication & Citation Trends
Publications
46 total
Leveraging training expertise to build capacity in computational personalised medicine
Cited by 0
Semantic Scholar
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, <i>EGFR</i> -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
Cited by 94
OpenAlex
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
Cited by 100
OpenAlex
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) PDF
Cited by 48
OpenAlex
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC PDF
Cited by 433
OpenAlex
ASTRIS: A Global Real-World Study of Osimertinib in >3000 Patients with <i>EGFR</i> T790M Positive Non-Small-Cell Lung Cancer
Cited by 57
OpenAlex
Relevent and LaLiga: Bringing Spanish Soccer to America
Cited by 0
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(19)
Lung Cancer Diagnosis and Treatment
(11)
Cancer Immunotherapy and Biomarkers
(7)
Gastric Cancer Management and Outcomes
(6)
TGF-β signaling in diseases
(5)
Affiliations
University of Geneva
National Institutes of Health
Harvard University
Government of India
Barcelona Supercomputing Center